Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to DOR/3TC/TDF vs Maintaining INSTI for Weight Loss in HIV
NCT06602622Phase 4Recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of doravirine, lamivudine, tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by Instituto Mexicano del Seguro Social. Started Aug 2024; status: recruiting.
02
Drugs
doravirinelamivudinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06602622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602622.